RNID is the largest not-for-profit organisation representing people with hearing loss and tinnitus in the UK. These are areas of high unmet medical need; WHO estimates almost half a billion people worldwide are affected with disabling hearing loss. There are currently no biomedical treatments to protect or regenerate hearing or silence tinnitus. RNID’s goal is to accelerate the development of these therapeutics.
The Cell and Gene Therapy (CGT) Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, the CGT Catapult’s mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies.
Based on the 12th floor of Guy’s Hospital in central London, with over 170 cell and gene therapy experts, state-of-the art development and viral vector laboratories. As well as a recently built £55m large-scale GMP manufacturing centre in Stevenage to help bring cell and gene therapies to market in the UK and internationally.
Medicines Discovery Catapult is a national facility connecting the UK community to accelerate innovative drug discovery. Funded by Innovate UK, an agency of the UK government, Medicines Discovery Catapult is an independent not-for-profit company.
It brings together a fragmented sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups, maximising impact through collaboration.
Medicines Discovery Catapult provides unique scientific capabilities and know-how in drug-discovery, facilitating access to specialist facilities, technology and expertise within the UK, supporting SMEs to drive the development and widespread use of new approaches for the discovery and early development of new medicines.
The National Institute for Health Research (NIHR) is the nation’s largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. The NIHR support hearing research through a number of its Biomedical Research Centres.
Manchester BRC is a world leading infrastructure for hearing research. Driving hearing health improvements through life-changing research that bridges the gap between new discoveries and individualised care. With the UK’s only Hearing Device Research Centre (HDRC), it drives innovation and accelerates the translation of technologies into the NHS.
The BRC partnership between the University of Manchester and Manchester University NHS Foundation Trust collaborates with national and international researchers, professional bodies and charities, to offer industry access to world class facilities. The trans-disciplinary team has an established portfolio that includes new discoveries in prevention, minimising risk, diagnosis and treatment.
Supported by NIHR infrastructure funding, the partnership between the University of Nottingham and Nottingham University Hospitals NHS Trust has since established itself as a flagship research centre addressing major clinical issues in the ENT and audiological management of hearing loss and tinnitus.
The Nottingham BRC offers some of the best infrastructure in the UK for supporting early-phase translational research in the hearing sciences. In particular, the commitment is to pursue research through multi-disciplinary collaboration that can be translated into practical benefits for patients.
The NIHR University College London Hospitals (UCLH) BRC Deafness and Hearing Problems theme builds on the unique partnership of the University College London Ear Institute and the Royal National ENT and Eastman Dental Hospitals. Embedded in one of the top universities in Europe and the only dedicated ENT hospital in the UK, the UCLH BRC provides the infrastructure and excellence to deliver world-leading translational research in the field of hearing loss.
Leading some of the world’s first early phase trials of hearing therapeutics developed to protect and restore hearing, the UCLH BRC advises global biotechnology and pharmaceutical companies on the design and delivery of such trials. The BRC spans from wet lab research, auditory neuroscience and developing proof-of-concept to clinical trials, analysis of routine hearing health data, health economics and policy, thus supporting forward and reverse translation to advance the field of novel hearing therapeutics.